teoglycans (HSPGs) participate in diverse biochemical and physiological processes via interactions with a variety of proteins. HP/HS and HSPGs bind and modulate activities of growth factors (3), maintain extracellular matrix integrity (4, 5) , modulate hemostasis (6) , participate in cell adhesion, growth, and differentiation (7) , and regulate smooth muscle cell proliferation (8, 9) . Studies in our laboratory have demonstrated that HP/HS and HSPGs are involved in the initial stages of mouse embryo implantation. HSPGs can be detected as early as the two-cell stage (10) , and HSPG expression on cell surfaces of mouse blastocysts increases 4 -5-fold at the peri-implantation stage (11) (12) (13) . Inhibition of HSPG synthesis or enzymatic removal of HS from blastocyst surfaces inhibits embryo attachment (12, 14) . Mouse embryo attachment to fibronectin, laminin, and isolated mouse uterine epithelial cells is HP/HSdependent (11) . Complementary specific, high affinity HP/HS sites on the cell surface of mouse uterine epithelial cells also have been characterized (15) . Thus, it is suggested that HSPGs and their corresponding binding sites are involved in the initial attachment of mouse embryos to uterine epithelium.
The initial attachment of the human trophoblastic cell line, JAR, to RL95 cells, a human uterine epithelial cell line, is HP/HS-dependent (16) . Furthermore, a single class of highly specific, cell surface HP/HS-binding sites has been identified on RL95 cell surfaces (17) . Cell surface, HP/HS-binding peptides were isolated from RL95 cells, and partial NH 2 -terminal amino acid sequence was obtained. A full-length cDNA sequence corresponding to one of these peptides was identified (1) . Predicted peptide sequence from this cDNA revealed an antigenic sequence that also has features expected for a HP/HS-binding motif (18) . Polyclonal antibodies directed against this synthetic peptide recognize a novel HP/HS-interacting protein (HIP) with a M r on SDS-polyacrylamide gel electrophoresis of 24,000. HIP is expressed by a variety of epithelial and endothelial cells and cell lines and on RL95 cell surfaces (1, 2) . In addition, HIP is highly expressed by human cytotrophoblast at the fetalmaternal interface throughout pregnancy in juxtaposition to a potential HSPG ligand, perlecan (19) . Previous studies (20) suggested that a large fraction of the HP/HS binding and cell adhesion promoting activity of intact HIP is attributable to this same peptide sequence.
In this paper, we describe functional studies on the synthetic peptide corresponding to this putative HP/HS-binding motif: CRPKAKAKAKAKDQTK, referred to as HIP peptide. The current studies demonstrate that HIP peptide is a highly selective HP/HS-binding peptide, recognizes certain forms of HP and cell-and extracellular matrix-associated HS expressed by human cell lines, and can support the HS-dependent attachment of a human trophoblastic cell line. Therefore, this peptide motif can account, at least in part, for the HS/HP binding and adhesion promoting activities of HIP.
EXPERIMENTAL PROCEDURES
Materials-Heparin, bovine kidney heparan sulfate, bovine intestinal mucosa heparan sulfate, chondroitin sulfates A and C, dermatan sulfate, keratan sulfate, hyaluronic acid, heparin disaccharides, chondroitinases AC and ABC, heparinases I, II and III, BSA, and CHAPS were purchased from Sigma. [6- 3 H]Glucosamine was purchased from ARC, Inc. (St. Louis, MO). Trypsin/EDTA solution, tissue culture media, and supplements were from Irvine Scientific (Santa Ana, CA). Fetal bovine serum, and Dulbecco's phosphate-buffered saline (PBS) were from Life Technologies, Inc.. Guanidine hydrochloride was purchased from U. S. Biochemical Corp. Imject activated immunogen conjugation kits were purchased from Pierce. All chemicals used were reagent grade or better.
Cell Culture-JAR and RL95 cells were grown in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F-12 medium (F-12) containing 10% (v/v) heat-inactivated fetal bovine serum, 15 mM Hepes, pH 7.4, 50 units of penicillin/ml, and 50 g of streptomycin sulfate/ml.
Peptide Synthesis, Conjugation to Maleimide-activated BSA, and HIP Peptide Affinity Chromatography-A synthetic peptide (HIP peptide) derived from HIP, a novel cell surface HS/HP-binding protein (1, 2) , CRPKAKAKAKAKDQTK, and a randomly scrambled peptide, CQKAKTRAKAAKPDKK, were synthesized on a Vega 250 peptide synthesizer using Fmoc (N-(9-fluorenyl)methoxycarbonyl) methodology (21) . This synthetic peptide was conjugated to maleimide-activated BSA (Pierce) through the sulfhydryl group of cysteine in the peptide following the coupling protocol provided by the manufacturer. HIP peptide affinity matrix was formed by cross-linking the BSA-conjugated HIP peptide to cyanogen bromide-activated Sepharose (Sigma) in the presence of N-acetylated HP. Inclusion of acetylated HP was adopted to produce a more stable affinity matrix by shielding the HP-binding sites of the HIP peptide complex from cross-linking to the Sepharose beads. Acetylation of HP was performed following the method described previously (22) . In a parallel study, three distinct affinity classes of HP, peaking at 0.15 M NaCl, 0.3 M NaCl, and 2.2 M NaCl, respectively, were separated by HIP peptide affinity chromatography using gradient elution (23) . Therefore, in most cases, stepwise elution of HIP peptide affinity chromatography was employed. The HIP peptide affinity matrix was packed into a 3-ml column and equilibrated with 0. The following day, the medium was collected and the cell layers were rinsed several times with ice-cold PBS. The cell layers then were incubated for 30 min on ice with PBS containing 50 g/ml trypsin to release cell surface proteoglycans. Cells were not released from the tissue culture surfaces under these conditions, nor was cell viability compromised as indexed by trypan blue exclusion. The material released into the "trypsinate" was collected, the cell layers were rinsed several more times with ice-cold PBS, and the cells scraped from the tissue culture surface with a rubber policeman into ice-cold water. The trypsinate was placed in a boiling water bath for 2-3 min and immediately cooled on ice to inactivate the trypsin. Isolation of 35 S-labeled extracellular matrix was performed following the method described (24) . Briefly, approximately 50% confluent cultures of RL95 cells were labeled with the same H 2 [ 35 S]O 4 -containing low sulfate medium as described above for 3 days. Cells then were washed with PBS twice, and dissolved with PBS containing 0.5% (v/v) Triton X-100 and 20 mM NH 4 OH for 5 min at room temperature. Afterward, the dish was washed four times with PBS, and the extracellular matrix was collected using a rubber policeman. All fractions then were precipitated with 10% (w/v) trichloracetic acid, 3% (w/v) phosphotungstic acid as described previously (25) . The pellets were resuspended in 1-2 ml of 0.5 M urea, 20 mM Tris-HCl, pH 8.0, 0.01% (w/v) octylglucoside, 0.02% (w/v) sodium azide and fractionated by Mono Q anion exchange chromatography exactly as described (25) . The material eluting from the column with 2-4 M NaCl constituted 90% or more of the total radioactivity in all cases and was pooled and extensively dialyzed against PBS. [ 35 S]HS or [ 35 S]DS was isolated following ␤-elimination as described (11) and used for HIP peptide binding assays. The size of RL95 cell surface-derived 35 S-labeled HS used for the solid phase binding assays was determined as described (26) . Specific activity was calculated based on the specific activity used for metabolic labeling (50 Ci/nmol) and assuming an average sulfate content of 1.5 sulfate residues/HS disaccharide unit. Where indicated, the fractions were further analyzed by digestion with glycosaminoglycan lyases or nitrous acid as described in detail previously (16) . HS was defined as sensitive (Ͼ95%) to nitrous acid digestion and insensitive to chondroitinase AC or ABC digestion. Dermatan sulfate was defined as sensitive (Ͼ95%) to chondroitinase ABC digestion, but insensitive to chondroitinase AC or nitrous acid digestion.
Structural Characterization of HS Fractions-35 S-or 3 H-labeled HS fractions from RL95 cells were prepared as described above and exhaustively digested with Pronase and subjected to mild alkaline hydrolysis to remove associated peptides as described (25) . Residual chondroitin and dermatan sulfate contaminants were removed by digestion with chondroitinase ABC as described previously (25) . RT-HS, LA-HS, and HA-HS were prepared by stepwise salt elution from a HIP peptide affinity matrix as described above. HS disaccharides were prepared by digestion at room temperature with 1 unit/ml each of heparinase I, II, and III (Sigma) in 20 mM Tris acetate (pH 7.0) plus 2 mM CaCl 2 and 2 mM MgCl 2 . After 24 h an additional 1 unit/ml amount of each enzyme was added. Mono Q anion exchange liquid chromatography was performed on these fractions using 2 M urea, 20 mM Tris acetate (pH 7.0), 0.02% (w/v) sodium azide as buffer A and the same buffer containing 4 M NaCl as buffer B. The column was run at room temperature at a flow rate of 1 ml/min. The gradient conditions were: 3 min of buffer A followed by a 25 min linear gradient to 100% buffer B, followed by 2 min during which 100% buffer B was maintained. Fractions were collected every minute and analyzed by liquid scintillation counting. Recoveries of radioactivity were routinely Ͼ95%. Superose 12 liquid chromatography was performed exactly as described previously (25) . Strong anion exchange liquid chromatography was performed to analyze HS disaccharides and was patterned after Tekotte et al. (27) with several modifications. A 4.6 mm (inner diameter) ϫ 25-cm Hydropore-5-AX HPLC column (Rainin Instrument Co., Inc., Woburn, MA) was equilibrated with 0.2 M NaCl (pH 3.5) as buffer 1 and 2 M NaCl used as buffer 2. The column was eluted at a flow rate of 1 ml/min at room temperature. The gradient conditions were 100% buffer 1 for 4 min, followed by a 4-min linear gradient to 25% buffer 2, maintenance of 25% buffer 2 for 12 min, followed by a step increase to 55% buffer 2, which then was maintained for 16 min followed by a 3-min linear gradient to 100% buffer 2 to elute any residual material. Every sample run included the presence of 10 g of a heparin disaccharide mix containing equal amounts of eight heparin disaccharide standards described in the legend to Fig. 5 . Elution of these internal standards was monitored at 232 nm using a Beckman model 163 flow-through variable wavelength spectrophotometer. Fractions were collected every 0.5 min, and elution of radioactivity was determined by liquid scintillation counting. Recoveries of radioactivity exceeded 95% in all cases. 5 dpm/well (approximately 300 nM) along with 0.1% (w/v) BSA and 0.1% (w/v) CHAPS in PBS) was added, and incubated in a 37°C incubator overnight. There were no differences in the amount of [ 3 H]HP bound after two to four washes under these conditions. Therefore, the amount of bound radioactivity detected after three washes was considered to represent a functional equilibrium and was used to calculate K D (app) 35 S]HS) was extracted from each well by overnight incubation at 37°C with 100 l of extraction buffer: 4 M guanidine HCl, 25 mM Tris-HCl, pH 8.0, 2.5 mM EDTA, and 0.02% (w/v) sodium azide. Half of the extract was counted in a Beckman scintillation counter.
Cell Attachment Assay of HIP Peptide-Cell attachment assays employed 24-well tissue culture plates (Costar). Each well was coated either with 200 l of BSA-conjugated HIP peptide (100 g/ml) or with the same amount of other controls. The plates were incubated in a 37°C incubator. The next day, each well was rinsed with 0.5 ml of PBS three times. Subsequently, 500 l of 0.1% (w/v) heat-denatured BSA in PBS was added to each well and incubated at 37°C for at least 1 h. Each well was rinsed again with 0.5 ml of PBS three times prior to the addition of cells. JAR cells were grown to approximately 90% confluence. Cells were detached with trypsin/EDTA solution for 5 to 10 min at 37°C, washed with DMEM/F-12 (1:1) plus 0.1% (w/v) BSA three times, and resuspended in DMEM/F-12 (1:1) plus 0.1% (w/v) BSA. This cell suspension (5-10 ϫ 10 4 cells/well) was then added to the wells coated as described above, and incubated in a 37°C incubator for the time periods indicated in each experiment. At the end of each experiment, unattached cells were gently rinsed away with 0.5 ml of PBS three times, and the relative cell attachment was determined using the hexosaminidase assay as described (28) .
Glycosaminoglycans (GAG) Competition and the Effects of GAG Lyases on JAR Cell Attachment to HIP
Peptide-A variety of GAGs, including unlabeled HP, bovine kidney HS bovine intestinal mucosa HS, chondroitin sulfates A and C, dermatan sulfate, keratan sulfate, and hyaluronic acid, were used as competitors in assays of cell attachment to HIP peptide. Different GAGs (100 or 200 g/ml as indicated) were included in the incubation medium for cell attachment assay in the competition studies. To determine if cell surface HP/HS or other GAGs of JAR cells mediate JAR cell attachment to HIP peptide, some cell attachment assays were performed in the presence of different GAG lyases (500 milliunits/ml), including heparinases I, II, and III, chondroitinases AC and ABC, with the addition of a protease inhibitor solution (11).
RESULTS

[
3 H]HP Binding to HIP Peptide-Solid phase assays were employed to determine the HP/HS binding activity of HIP peptide. Preliminary studies established that a coating concentration at 100 g/ml HIP peptide in PBS gave optimal binding for both [ 3 H]HP and cell attachment. Furthermore, [ 3 H]HP did not bind to BSA or BSA conjugated to an irrelevant peptide (CSSLSYTNPAVAATSANL) corresponding to the cytoplasmic tail region of the mucin, MUC1 (29) . Therefore, 100 g/ml HIP peptide was used typically in [ 35 S]HS binding and cell attachment studies. In addition, solid-phase assays also were performed using HIP peptide not conjugated to maleimide-activated BSA as coating material, and similar results were obtained as described above for BSA-conjugated HIP peptide (data not shown). Collectively, these results demonstrate HP binding was to HIP peptide and not the BSA carrier. [ 3 H]HP binding also was time-dependent, reaching maximal values within 10 -15 min (data not shown).
As shown in Fig. 1A , [ 3 H]HP binding to HIP peptide is concentration-dependent with a 50% saturation at approximately 245 nM when these data are analyzed as a Scatchard plot (Fig. 1A, inset) . Four separate experiments yielded an average 50% saturation point of 300 nM. A peptide with the same amino acid composition as HIP peptide, but with a scrambled sequence, CQKAKTRAKAAKPDKK, bound [ 3 H]HP with a 10 -20-fold lower affinity than HIP peptide (data not shown). Therefore, the peptide sequence, rather than composition, was crucial to obtain high affinity binding. In a parallel study, HIP peptide affinity chromatography of commercial [ 3 H]HP revealed three affinity classes of HP (RT-HP, LA-HP, and HA-HP) with regard to binding to HIP peptide (23) . To determine the affinity of HA-HP binding to HIP peptide, HA-HP was collected and subjected to the solid-phase HIP peptide binding assay. Fig. 1B (Fig. 2, inset) . Collectively these studies demonstrated that HIP peptide binds HP much more selectively than other GAGs. Fig. 3 shows that, in solid-phase assays, [ 35 S]HS isolated from RL95 cell surfaces binds to HIP peptide in a concentration-dependent and saturable fashion. Previous studies established the median molecular weight of cell surface HS chains of RL95 cells (26) . Assuming the specific activity of the [
Cell Surface and Extracellular Matrix-associated HS Binds to HIP Peptide-
35 S]sulfate in these HS preparations was similar to that of the sulfate precursor used for metabolic labeling, a 50% saturation point of approximately 0.2 nM was estimated. Inclusion of 100 g/ml unlabeled HP inhibited almost all of this binding (Ͼ90%). Furthermore, HS isolated from cell surfaces of various breast cancer cell lines also specifically binds to HIP peptide (30) . Collectively, these data illustrate that certain forms of HS expressed at the cell surface or the extracellular matrix by human cells binds to HIP peptide.
Given the ability of dermatan sulfate to partially compete for [ 3 Fig. 4 (A and B, respectively) . These experiments demonstrate that a much higher percentage of cell-associated glycosaminoglycans bound to HIP peptide than secreted forms. In most fractions, bound glycosaminoglycans eluted between 0.2 and 0.3 M NaCl; however, cell surface HS contained higher affinity species that required more than 0.4 M NaCl for elution. RL95 cells representing secreted or released, cell surface (cellassociated and trypsin-releasable), intracellular (cell-associated, but not trypsin-releasable) and extracellular matrix forms. Each fraction was further separated by affinity on a HIPpeptide affinity matrix into three additional fractions. These fractions were: 1) material that did not bind at physiological salt concentrations (RT-HP); 2) material that bound at physiological salt concentrations, but could be eluted with 0.45 M NaCl (LA-HP); and 3) material that remained bound at 0.45 M NaCl, but could be eluted with 3 M NaCl (HA-HP). Each fraction was characterized further by several methods. Anion exchange liquid chromatography (Fig. 5A ) demonstrated that cell surface-derived LA-and HA-HS had a slightly higher negative charge density than RT-HS; however, there were no detectable differences in this regard between LA-and HA-HS. These differences between RT-HS and the other HS fractions were found not only in cell surface HS fractions (shown in figure) , but also in all other HS fractions examined (data not shown). Molecular exclusion chromatography (Fig. 5B ) demonstrated that LA-or HA-HS fractions that bound to HIP peptide were generally larger (median mass Ͼ 70 kDa relative to polysaccharide standards) than RT-HS (median mass Ͻ 70 kDa). HA-HS was skewed toward lower molecular mass forms relative to LA-HA. These observations were consistently observed in HS derived from the cell surface (shown in figure) as well as secreted, extracellular matrix-associated, and intracellular forms of HS (data not shown).
HS disaccharides generated by exhaustive digestion with a heparinase mixture revealed additional structural differences in HS species that interacted with HIP peptide. A representative disaccharide profile is shown in Fig. 6 . The data obtained from all HS fractions are summarized in Table II . In general, RT-HS fractions from all cellular compartments were poorly sulfated with a very high fraction of nonsulfated disaccharides (53-97%). Nonsulfated disaccharides also represented a higher proportion of the total in LA-HS (43-53%) than HA-HS (24 -38%). In contrast, HA-HS species were greatly enriched for diand trisulfated disaccharide species (35-55%). LA-HS species had a larger proportion of di-and trisulfated disaccharides (22-30%) than RT-HS and displayed intermediate proportions of di-and trisulfated disaccharides (18 -22%) relative to HA-HS. LA-HS fractions also were generally enriched for monosulfated species relative to RT-HS (10 -22% versus 3-15%, respectively). Collectively, these studies indicated that there were structural differences not only between the HS species that bound or did not bind to HIP peptide, but also between the 
TABLE I Binding of HS and DS Fractions to HIP peptide
HS and DS fractions from either RL95 or JAR cells were prepared as described under "Experimental Procedures." In each case, the glycosaminoglycan fraction was applied to the column and eluted in PBS until only background levels of radioactivity were detected in the eluate. Then the resin was either subjected to linear or step gradient elution with NaCl up to 3.0 M. The total bound radioactivity is shown in each case. A range of values is shown for [ 3 H]HP to indicate the variability observed with different HP preparations. With exception of the JAR cell surface dermatan sulfate fraction, more than 100,000 dpm were used in each analysis. Approximately 18,000 dpm of JAR cell surface dermatan sulfate was used. Secreted refers to glycosaminoglycans isolated from the medium, ECM refers to glycosaminoglycans isolated from extracellular matrix preparations, cell surface refers to glycosaminoglycans isolated from material released from intact cell layers by mild trypsinization, and trypsin-resistant refers to glycosaminoglycans isolated from material remaining in the cell-associated fraction after mild trypsinization. species that bound with low versus high affinity. JAR Cell Attachment to HIP Peptide-JAR cells, a human trophoblastic cell line derived from a placental choriocarcinoma (31) , was used in a detailed examination of cell attachment to HIP peptide. As described above, preliminary studies determined that 100 g/ml peptide was an optimal coating concentration and was used for routine JAR cell attachment assays. Kinetic studies showed that JAR cell attachment to HIP peptide was time-dependent with near maximal attachment observed between 4 and 8 h of incubation at 37°C (data not shown). Thus, the routine JAR cell attachment assays were performed using 4 -6-h incubations. Table III shows that JAR cells attached to HIP peptide, and more than 90% of this attachment was inhibited in the presence of 1 mg/ml HP. Heatdenatured BSA, used to block nonspecific binding sites after coating, did not support JAR cell attachment. JAR cells attached well to fibronectin (FN); however, attachment to FN was not inhibited by 1 mg/ml HP. CT-1 peptide, a peptide sequence corresponding to a cytoplasmic region of the human epithelial mucin, MUC1 (29) , conjugated to maleimide-activated BSA also was used as a nonspecific peptide control as well as a control for the activated BSA used in HIP peptide conjugation, and did not support JAR cell attachment. Thus, JAR cells specifically attached to HIP peptide in a HP-inhibitable fashion. The calculated pI of HIP peptide is relatively high (Х9.9). Therefore, it was considered that JAR cell attachment to HIP peptide was due to a nonspecific charge effect; however, lysozyme (pI ϭ 10.5-11.0), failed to support JAR cell attachment. Furthermore, JAR cells also failed to attach to a peptide containing a randomly scrambled sequence of the same amino acid composition and therefore, identical pI, as the HIP peptide. As an additional test of the specificity of cell attachment to HIP peptide, surfaces were coated with HIP peptide and soluble HIP peptides or a scrambled peptide were used as competitors. As shown in Table IV, soluble HIP peptide at 100 g/ml effectively inhibited cell attachment; however, the scrambled sequence, even at 500 g/ml, had little effect in this regard. Consequently, cell recognition of HIP peptide appeared to be sequence-specific. 35 S]O 4 -Labeled derived from RL95 cell surfaces were prepared and fractionated by stepwise HIP-peptide affinity chromatography as described under "Experimental Procedures." These fractions then were analyzed either by anion exchange chromatography on Mono Q (A) or molecular exclusion chromatography on Superose 12 (B) as described under "Experimental Procedures." Fractions were collected every minute in each case and the profile of the total radioactivity eluting in each fraction determined by liquid scintillation counting is shown. RT-HS (E) or run-through HS refers to HS that did not bind to HIP peptide at physiological salt concentrations; LA-HS (q) refers to low affinity HS or HS that bound at 0.15 M NaCl, but could be eluted with 0.45 M NaCl; HA-HS (‚) or high affinity HS refers to HS that remained bound at 0.45 M NaCl, but could be eluted with 3 M NaCl. The dashed line in A shows the salt gradient used. The elution positions of the following size markers is shown in B: V o , blue dextran with molecular weight Ͼ 2 ϫ 10 6 ; 531K, dextran with a median molecular weight of 531,000; 71K, dextran with a median molecular weight of 71,000; 12K, commercial HP with a median molecular weight of 12,000; V t , potassium dichromate.
FIG. 6. Anion exchange liquid chromatography of HS disaccharides. [
3 H]Glucosamine-labeled HS derived from RL95 cell surfaces was prepared and fractionated by stepwise HIP-peptide affinity chromatography as described under "Experimental Procedures." These fractions then were digested to completion with a heparinase mixture and analyzed by strong anion exchange liquid chromatography on a Hydropore-5-AX column as described under "Experimental Procedures." Fractions were collected every 0.5 min, and the profile of the radioactivity eluting in each fraction as determined by liquid scintillation counting is shown. The numbers above the peaks refer to the elution positions of the following disaccharides used as internal controls and monitored by measuring A 232 using a flow-through spectrophotometer (where ⌬UA represents 4-deoxy-␣-L-threo-hex-4-enopyranosyluronic acid, GlcNAc represents 2-acetamido-2-deoxy-D-glucose, and GlcNS represents 2-de-
HP Sensitivity and Glycosaminoglycan Selectivity of JAR
Cell Attachment to HIP Peptide-GAG selectivity of JAR cell attachment to HIP peptide was determined using different GAGs as competitors. Fig. 8 shows that HP was the most effective inhibitor among all GAGs tested. Dermatan sulfate and keratan sulfate also displayed inhibitory activity at a concentration of 200 g/ml, but other GAGs did not significantly inhibit cell attachment to HIP peptide. Further studies on the inhibitory effect of different concentrations of HP, dermatan sulfate, and keratan sulfate demonstrated that both of the latter polysaccharides failed to inhibit JAR cell attachment activity at concentrations below 50 g/ml, i.e. about 100-fold higher concentrations than that required for HP (Fig. 8, inset) . In fact, very low concentrations (1 g/ml) of dermatan or keratan sulfate consistently stimulated JAR cell attachment to HIP peptide, although the reason for this is unclear. Additional studies demonstrated that JAR cell attachment to HIP peptide was inhibited more than 90% in the presence of 0.5 g/ml (approximately 50 nM) of HP. Therefore, JAR cell attachment to HIP peptide is highly selective for HP versus other GAGs.
To determine if HS on JAR cell surfaces mediated JAR cell attachment to HIP peptide, JAR cell attachment to HIP peptide was performed in the presence of different GAG lyases. GAG lyases were added to HIP peptide-coated wells in the presence of protease inhibitors (Fig. 9) . Hep 3 (a mixture of heparinases I, II, and III) inhibited JAR cell attachment to HIP peptide by approximately 90%. In contrast, chondroitinase ABC inhibited attachment to a lesser extent (55%); however, chondroitinase AC was ineffective in this regard. Consequently, consistent with previous studies (16) , cell surface dermatan sulfate, but not chondroitin sulfate, appeared to participate in JAR cell binding to HIP peptide as well as HS. In addition, Fig. 9 shows that soluble HIP peptide as well as HP both effectively inhibited JAR cell attachment to HIP peptide. Collectively, these observations indicate that cell surface HS and, to a lesser extent, dermatan sulfate expressed by JAR cells mediate binding to HIP peptide. 3 H recovered in each respective fraction. Some disaccharides were not clearly resolved when collected into scintillation vials for counting. These unresolved components were grouped for the calculations as indicated. Abbreviations: RT, run-through from peptide affinity column; LA, material eluted from peptide affinity column with 0.45 M NaCl; HA, material that bound and that remained bound to the peptide affinity column at 0.45 M NaCl and eluted with 3 M NaCl; disaccharide abbreviations are as described in legend to Fig. 6 . ND, not detectable (Ͼ1%). HIP peptide 100 (17) . A full-length cDNA has been obtained corresponding to one of these fragments using approaches of reverse transcription-polymerase chain reaction and library screening (1) . Structural analysis of the predicted peptide sequence derived from this cDNA revealed a region that is composed of highly positive-charged amino acids separated by hydrophobic amino acids, a motif found in various HS/HP-binding proteins and suggested to function as a HS/HPbinding domain (18) . This region is hydrophilic and likely to be exposed at the exterior surface of the protein, where it might participate in HS/HP-binding events. Antibodies directed to this peptide react with RL95 cell surfaces and recognize a protein that binds HP in an 125 I-HP overlay assay and binds to HP-agarose with high affinity (2) . In the present studies, a synthetic peptide was synthesized corresponding to this putative HP/HS-binding region for functional studies. HP/HS binding to this simple peptide also was highly selective for certain forms of HP and HS and of comparable affinity to various intact HP/HS-binding proteins (32, 33 3 H]HP binds relatively poorly to both lysozyme and a scrambled sequence of the HIP peptide. Interestingly, dermatan sulfate is the only GAG other than HP that contains iduronic acid in its structure and has a small percentage of disulfated disaccharide units (34) . It has been suggested that the presence of iduronic acid in the polysaccharide chains provides more flexibility in polysaccharides which may facilitate their association with corresponding binding sites (34, 35) . HIP peptide binding species also are enriched for di-and trisulfated disaccharides as compared with nonbinding HS species. HS species that bound to HIP peptide with higher affinity (HA-HS) also were more enriched, in this regard, than the species that interacted with lower affinity (LA-HS). The enrichment with di-and trisulfated disaccharides is consistent with the higher negative charge density observed for LA-HS and HA-HS compared with RT-HS by anion exchange chromatography. Collectively, the present studies demonstrate that HIP peptide binds HP with a high degree of selectivity and suggest that the presence of iduronic acid and/or regions with a high degree of sulfation contribute to HP binding to HIP peptide.
A small fraction (approximately 1-5%) of enzyme that destroys these sequences (36) . Collectively, these observations strongly suggest that specific polysaccharide structures recognized by HIP peptide reside both in commercial HP preparations and certain forms of cell-expressed HS. Previously, we found that HA-HP binds to antithrombin III with particularly high affinity (23) , suggesting that HIP peptide recognizes the same well defined HP polysaccharide structure specifically recognized by antithrombin III (37) . Thus, HIP peptide can account, at least in part, for the HP/HS binding activity of the parental HIP protein. The HP/HS binding activity of the HIP peptide coupled with the cell surface disposition of HIP (2) and the affinity of cell surface and extracellular matrix forms of HS for HIP peptide (Ref. 30 , and present studies) strongly suggest that HIP participates in aspects of HS-dependent cell adhesion.
JAR cell attachment to HIP peptide was HS-dependent and not simply due to nonspecific charge effects. JAR cell attachment was much more sensitive to HP than the other GAGs tested with maximal inhibition achieved at HP concentrations of 0.5 g/ml. This concentration is approximately 50 nM, assuming an average molecular weight of 10,000 for HP chains and is consistent with the K D obtained for the high affinity fraction of HP. HS removal from JAR cell surfaces most efficiently (Ͼ90%) inhibited JAR cell attachment to HIP peptide, indicating that cell surface HS mediated this binding; however, dermatan sulfate displayed on JAR cell surfaces also may play a role. Previous studies demonstrated the presence of dermatan sulfate bearing molecules on JAR cell surfaces and indicated that this class of GAGs participated to some extent in adhesion between JAR and RL95 cells (16) . In the present studies, selective removal of dermatan sulfate, but not chondroitin sulfate, as well as HS from JAR cells also inhibited binding to HIP peptide. Partial (55%) inhibition was observed after digestion of JAR cells with chondroitinase ABC, which removes dermatan sulfates from JAR cell surfaces. In contrast, heparinases reduced binding by 90% or more. Soluble dermatan sulfate also inhibited JAR cell attachment, but was much less effective than HP. Collectively, these results demonstrate that HIP peptide specifically supports JAR cell attachment by binding HS expressed on JAR cell surfaces. Dermatan sulfate participates in this process, albeit to a lesser extent.
As discussed above, a number of studies in both mouse and human model model systems indicate that HSPGs and their corresponding binding proteins participate in blastocyst attachment to the uterine epithelium during the initial phases of implantation. HIP is expressed by human uterine epithelium throughout the menstrual cycle; moreover, the HIP peptide motif studied here has been shown to be accessible at cell surfaces (2) . Previous studies demonstrated that intact HIP supports the attachment of human trophoblastic cell lines (20) . More recently, we have determined that human cytotrophoblast not only express, but also appear to utilize this protein for aspects of trophoblast invasion as well as attachment to the HSPG, perlecan (19) . These same studies indicate that antibodies to this sequence inhibit trophoblast invasion in vitro. The interactions of the HIP peptide sequence with HS motifs important for susceptibility to heparanase action, anticoagulant activity and trophoblast attachment indicate that HIP has the potential to play a key role in HS-dependent processes in developing and adult tissues.
